[go: up one dir, main page]

MA38227A1 - Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase - Google Patents

Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase

Info

Publication number
MA38227A1
MA38227A1 MA38227A MA38227A MA38227A1 MA 38227 A1 MA38227 A1 MA 38227A1 MA 38227 A MA38227 A MA 38227A MA 38227 A MA38227 A MA 38227A MA 38227 A1 MA38227 A1 MA 38227A1
Authority
MA
Morocco
Prior art keywords
lactamase
inhibitors
antibacterial agents
bicyclic compounds
novel bicyclic
Prior art date
Application number
MA38227A
Other languages
English (en)
Other versions
MA38227B1 (fr
Inventor
Samarendra N Maiti
Jehangir Khan
Dai Nguyen
Rong Ling
Original Assignee
Fedora Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fedora Pharmaceuticals Inc filed Critical Fedora Pharmaceuticals Inc
Publication of MA38227A1 publication Critical patent/MA38227A1/fr
Publication of MA38227B1 publication Critical patent/MA38227B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Medicine (AREA)

Abstract

L'invention concerne un composé de formule (i), dans laquelle m est hydrogène ou un cation formant un sel pharmaceutiquement acceptable; y est or1 ou nr2r3, et r1, r2, r3 et m sont tels que définis ici. L'invention concerne également des méthodes de traitement d'une infection bactérienne, des compositions pharmaceutiques, des complexes moléculaires et des procédés pour la préparation des composés.
MA38227A 2012-12-11 2012-12-11 Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase MA38227B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/002675 WO2014091268A1 (fr) 2012-12-11 2012-12-11 Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase

Publications (2)

Publication Number Publication Date
MA38227A1 true MA38227A1 (fr) 2016-12-30
MA38227B1 MA38227B1 (fr) 2017-10-31

Family

ID=50933808

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38227A MA38227B1 (fr) 2012-12-11 2012-12-11 Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase

Country Status (18)

Country Link
EP (1) EP2931723B1 (fr)
JP (1) JP2016503000A (fr)
KR (1) KR20150093809A (fr)
CN (1) CN105873930B (fr)
AU (1) AU2012396338B2 (fr)
BR (1) BR112015013450A8 (fr)
CA (1) CA2893804C (fr)
CR (1) CR20150359A (fr)
EA (1) EA028633B1 (fr)
EC (1) ECSP15029636A (fr)
ES (1) ES2817785T3 (fr)
IL (1) IL239116B (fr)
MA (1) MA38227B1 (fr)
MX (1) MX2015007406A (fr)
PH (1) PH12015501303A1 (fr)
SG (1) SG11201504540TA (fr)
UA (1) UA111925C2 (fr)
WO (1) WO2014091268A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2857401T (pt) * 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
WO2015110886A1 (fr) * 2014-01-21 2015-07-30 Wockhardt Limited Procédé de préparation de (2s, 5r)-7-oxo-n-[(3s)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide
CN105801579A (zh) * 2014-12-31 2016-07-27 卢来春 一种β-内酰胺酶抑制剂
WO2016120752A1 (fr) * 2015-01-28 2016-08-04 Wockhardt Limited Procédé de préparation de (2s, 5r)-n-(2-aminoéthoxy)-6-(sulfooxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
WO2017002087A1 (fr) * 2015-07-02 2017-01-05 Wockhardtlimited Composés bicycliques contenant de l'azote et leur utilisation dans le traitement d'infections bactériennes
CA2984024A1 (fr) 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. Inhibiteurs de beta-lactase et utilisations associees
TW201725205A (zh) 2015-10-02 2017-07-16 樂高化學生物科學股份有限公司 用於抑制β-內醯胺酶之組合物及方法
WO2017081615A1 (fr) * 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1] octane contenant des composés et leur utilisation dans le traitement d'infections bactériennes
KR20180094042A (ko) * 2015-12-11 2018-08-22 욱크하르트 리미티드 7-옥소-6-(설포옥시)-1,6-디아자바이사이클로[3.2.1]옥탄-2-카르복사미드 함유 화합물 및 이의 세균 감염의 치료 용도
DK3464336T3 (da) 2016-06-01 2022-05-09 Athira Pharma Inc Forbindelser
EP3466950B1 (fr) 2016-06-03 2021-02-24 Qilu Pharmaceutical Co., Ltd. Nouveaux inhibiteurs de la bêta-lactamase
WO2017206948A1 (fr) * 2016-06-03 2017-12-07 南京明德新药研发股份有限公司 Nouveau diazabicyclo b-lactamase inhibiteurs
WO2017216763A1 (fr) * 2016-06-17 2017-12-21 Wockhardt Limited Dérivés de n-phénylalcoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide et leur utilisation en tant qu'agents antibactériens
WO2017216764A1 (fr) * 2016-06-17 2017-12-21 Wockhardt Limited Dérivés de n-(alcanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide et leur utilisation comme agents antibactériens
JP7012924B2 (ja) * 2017-03-02 2022-02-15 ウォックハート リミテッド 抗菌化合物としての複素環誘導体
CN106831772B (zh) * 2017-03-04 2019-12-17 丽珠医药集团股份有限公司 一种阿维巴坦中间体的合成方法
WO2018203197A1 (fr) * 2017-05-02 2018-11-08 Wockhardt Limited Dérivés de diazabicyclooctane comprenant un groupe oxyimino destiné à être utilisé en tant qu'agents antibactériens
WO2018203194A1 (fr) * 2017-05-02 2018-11-08 Wockhardt Limited Dérivés de diazabicyclooctane comprenant un groupe d'ammonium quaternaire destiné à être utilisé en tant qu'agents antibactériens
CN107383034A (zh) * 2017-06-29 2017-11-24 上海药明康德新药开发有限公司 外消旋‑5‑(叔丁氧羰基)‑八氢呋喃并[3,2‑c]吡啶‑3a‑羧酸的合成方法
MA49623A (fr) 2017-07-21 2021-03-17 Antabio Sas Composés chimiques
WO2019064071A1 (fr) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag Formes cristallines de dérivés de diazabicyclooctane et leur procédé de production
ES2928152T3 (es) 2017-12-01 2022-11-15 Qilu Pharmaceutical Co Ltd Forma cristalina de un inhibidor de beta-lactamasa y método de preparación de la misma
EP3572411A1 (fr) 2018-05-21 2019-11-27 Antabio SAS Dérivés de thiazole comme inhibiteurs de métallo-bêta-lactamases
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3608318A1 (fr) * 2018-08-09 2020-02-12 Antabio SAS Derives de diaazabicyclooctanone comme antibiotiques
CN113292499B (zh) * 2020-02-24 2024-05-28 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的新制备方法及其中间体
CN117384169B (zh) * 2022-07-05 2025-10-17 福安药业集团重庆三禾兴医药科技有限公司 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337197A (en) 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CL2007003444A1 (es) 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
TWI565706B (zh) * 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
AU2012303691B2 (en) * 2011-08-27 2014-06-19 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
PT2857401T (pt) * 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
WO2014033560A1 (fr) * 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes

Also Published As

Publication number Publication date
BR112015013450A2 (pt) 2017-07-11
CN105873930B (zh) 2019-02-19
BR112015013450A8 (pt) 2019-10-08
EA028633B1 (ru) 2017-12-29
PH12015501303A1 (en) 2015-08-24
ECSP15029636A (es) 2016-01-29
KR20150093809A (ko) 2015-08-18
IL239116B (en) 2019-05-30
CA2893804A1 (fr) 2014-06-19
MX2015007406A (es) 2015-12-03
CA2893804C (fr) 2021-05-18
EP2931723A1 (fr) 2015-10-21
SG11201504540TA (en) 2015-07-30
NZ709355A (en) 2017-09-29
AU2012396338B2 (en) 2017-09-28
JP2016503000A (ja) 2016-02-01
EA201500544A1 (ru) 2015-12-30
ES2817785T3 (es) 2021-04-08
UA111925C2 (uk) 2016-06-24
CR20150359A (es) 2015-08-20
CN105873930A (zh) 2016-08-17
EP2931723B1 (fr) 2020-08-26
IL239116A0 (en) 2015-07-30
AU2012396338A1 (en) 2015-07-16
WO2014091268A1 (fr) 2014-06-19
MA38227B1 (fr) 2017-10-31
EP2931723A4 (fr) 2016-06-01

Similar Documents

Publication Publication Date Title
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA35576B1 (fr) Nouveaux composés
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA37929B1 (fr) Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA35725B1 (fr) Composés pipérazines alkylés en tant qu'inhibiteurs de l'activité btk
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA34308B1 (fr) Triazolopyridines substituées
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA35444B1 (fr) Ligands du récepteur ep1
MA38385A1 (fr) Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma